Fontem Ventures questions recent Japanese public health study on Cigarettes01.12.14
“Fontem Ventures, one of the world’s leading producers of e-cigarettes, has expressed doubts over the recent results from a research report on e-cigarettes, which was conducted by Japanese scientists
Monday 1st December 2014 – “Fontem Ventures, one of the world’s leading producers of e-cigarettes, has expressed doubts over the recent results from a research report on e-cigarettes, which was conducted by Japanese scientists from the National Institute of Public Health in Japan.
The research team claims to have found that e-cigarettes contain 10 times the level of cancer-causing agents as regular tobacco, including formaldehyde and acetaldehyde, in the vapour produced by several types of unidentified e-cigarette brands.
Fontem Ventures, along with a number of other organizations including Electronic Cigarette Industry Trade Association (ECITA), questions the results of this recent study.
In November 2013, in one of the most comprehensive studies to date, Goniewicz et. al. of Tobacco Control, investigated the levels of compounds in 12 different EVP brands and compared the results against the Nicorette Inhalator, which is a pharmaceutical nicotine replacement product. The Tobacco Control research found that while certain toxic compounds in the EVP vapour including formaldehyde and acetaldehyde were found, they were at levels comparable to the trace amounts found in the Nicorette Inhalator – at 9 to 450 times lower than in cigarette smoke.
As a result, Fontem Ventures agrees with the conclusions of ECITA who also expressed serious doubts regarding the new report out of Japan. ECITA found that the recent research carried out by the Japan Public Health team appears to have been conducted on products of varying quality available on the Japanese market in 2013 and therefore does not reflect the UK market.
The Goniewicz et. al study concluded that substituting tobacco cigarettes with e-cigarettes may substantially reduce exposure to selected tobacco-specific toxicants and thus reduce adverse health effects.”